At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the clinical development of AZD9291, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of patients with EGFR T790M-mutant non-small cell lung cancer (NSCLC) following resistance to frontline anti-EGFR therapy.
AZD9291, an EGFR-TKI, for T790M-mediated resistance in non-small cell lung cancer
4th February 2016
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?